The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0711 GMT - Ipca Laboratories' earnings growth momentum looks strong after posting robust results in 1Q FY 2027, Nomura analysts say in a research report. Hence, management lifted its FY 2027 guidance for revenue growth to 14%-16% from 12%-13% previously, and for Ebitda margin to around 23% from roughly 22% earlier. Nomura also raises its sales estimates for the Indian pharmaceutical company by about 2.5% a year for FY 2027 and FY 2028. Ipca Laboratories' India formulation sales are expected to sustain low-teens percentage growth, the analysts say. The brokerage raises the stock's target price to 2,060.00 rupees from 1,725.00 rupees, with an unchanged buy rating. Shares are 0.1% lower at 1,881.05 rupees. (ronnie.harui@wsj.com)

0034 GMT - Cochlear's expectation of FY 2027 profit growth appears to be driven by operating costs rather than sales, Jarden analysts observe. They tell clients in a note that the hearing-implant maker's guidance for 5.5% net profit growth at the range midpoint comes despite its expectation that sales revenue will only grow by a percentage in the low single digits. They tell clients in a note that the profit guidance, which is in line with analysts' expectations, is supported by a slight on-year decline in operating costs. They think that the quality of the FY 2026 result was worse than anticipated, but see the FY 2027 outlook as positive. Jarden has a last-published neutral rating on the stock and a target price of 169.00 Australian dollars. Shares are up 5.0% at A$137.80. (stuart.condie@wsj.com)

0024 GMT - The composition of Cochlear's annual revenue should please investors, RBC analyst Craig Wong-Pan says. While the hearing-implant maker's FY 2026 revenue was broadly in line with consensus, Wong-Pan points out that the Australian company's implants and services units both performed more strongly than analysts had expected. This strength was partially offset by a miss from acoustics, he writes in a note. Overall, Wong-Pan expects the result to generate positive sentiment, with underlying earnings about 3% stronger than his above-consensus forecast. RBC has a last-published sector perform rating on the stock and a target price of 117.00 Australian dollars. Shares are up 2.1% at A$133.98. (stuart.condie@wsj.com)

2331 GMT [Dow Jones]--Australian pharmaceutical company CSL's share price looks a good bet to outperform today, RBC Capital Markets says. CSL's FY26 underlying earnings and revenue beat expectations. "We think the market will particularly like the immunoglobulin performance with FY26 revenue growth of 4% year-over-year and 2H26 growth of 14% on-year," analyst Craig Wong-Pan says. CSL expects FY27 revenue to match the FY26 outcome. It also expects underlying profit growth of 5% when currency swings are stripped out. This implies an underlying net profit of US$2.93 billion, above consensus hopes of US$2.83 billion. "The stock has had a strong run into this result, however we expect the FY27 guidance beat to consensus and strong immunoglobulin performance in 2H26 to drive outperformance in the stock today," RBC says. (david.winning@wsj.com; @dwinningWSJ)

1054 GMT - Sandoz's tie-up with China's Henlius looks like a positive step for the Swiss pharmaceutical company, RBC Capital Markets' Harry Sephton writes in a note to investors. Under the partnership, the two companies will collaborate on the development and commercialization of up to ten biosimilar medicines, with payments for the commercialization reaching up to $322 million. The agreement "demonstrates Sandoz's leading position as a commercialization partner in biosimilars," Sephton says. Sandoz shares gain 3.15% to 75.3 Swiss francs. (joshua.kirby@wsj.com' @joshualeokirby)

1040 GMT - AstraZeneca needs some positive pipeline news after a lung cancer drug Phase three trial was ended, BofA Securities' analysts write. The failure of volrustomig may increase investor caution about the oncology pipeline, they add. The genie is out of the bottle on AstraZeneca's concern around its patent cliff and pipeline, after reports of merger talks with Bristol Myers Squibb, the analysts say. However, data delivery can challenge this, BofA adds. Investors are cautious about higher-risk advanced cancer trials Serena-4 and Avanzar, but BofA says it sees a positive risk-reward balance. If the studies fail, the U.S. bank says it sees downside for the pharmaceutical company. Shares are up 1.0% in London. (michael.hennessey@wsj.com)

1020 GMT - AstraZeneca's discontinuation of one lung-cancer drug trial is disappointing, but positive data for other drugs could see an upgrade to consensus sales guidance, J.P. Morgan analysts say. The volrustomig trial, which has been scrapped after a review, was already seen as high risk. It represented around 20% of the sales target AstraZeneca has for the drug, which was set at more than $5 billion. However, the strength of results from Tagrisso and Orpathys trials--also possible lung-cancer treatments--are encouraging, according to the U.S. bank. Based on the results, a sales peak of at least $500 million for Orpathys appears more likely, as is $500 million more in sales for Tagrisso than expected, JPM says. Results of the Enhertu trial also suggest up to $500 million in peak sales for this drug. Shares are up 0.8%.